173 related articles for article (PubMed ID: 29216804)
21. Myeloid-Derived Suppressor Cells in Cancers and Inflammatory Diseases: Angel or Demon?
Su Z; Ni P; Zhou C; Wang J
Scand J Immunol; 2016 Nov; 84(5):255-261. PubMed ID: 27541573
[TBL] [Abstract][Full Text] [Related]
22. The potential therapeutic role of myeloid-derived suppressor cells in autoimmune arthritis.
Wang Y; Tian J; Wang S
Semin Arthritis Rheum; 2016 Feb; 45(4):490-5. PubMed ID: 26272193
[TBL] [Abstract][Full Text] [Related]
23. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
[TBL] [Abstract][Full Text] [Related]
24. The use of α-fetoprotein for the delivery of cytotoxic payloads to cancer cells.
Pak V
Ther Deliv; 2014 Aug; 5(8):885-92. PubMed ID: 25337646
[TBL] [Abstract][Full Text] [Related]
25. Activation of benign autoimmunity as both tumor and autoimmune disease immunotherapy: a comprehensive review.
Cohen IR
J Autoimmun; 2014 Nov; 54():112-7. PubMed ID: 24924121
[TBL] [Abstract][Full Text] [Related]
26. Targeting Myeloid-Derived Suppressor Cells in Cancer.
Anani W; Shurin MR
Adv Exp Med Biol; 2017; 1036():105-128. PubMed ID: 29275468
[TBL] [Abstract][Full Text] [Related]
27. The alpha-fetoprotein-derived growth inhibitory peptide 8-mer fragment: review of a novel anticancer agent.
Mizejewski GJ
Cancer Biother Radiopharm; 2007 Feb; 22(1):73-98. PubMed ID: 17627416
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy.
Lu B; Yang M; Wang Q
J Mol Med (Berl); 2016 May; 94(5):535-43. PubMed ID: 26922618
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic use of human alpha-fetoprotein in clinical patients: is a cancer risk involved?
Mizejewski GJ
Int J Cancer; 2011 Jan; 128(1):239-42. PubMed ID: 20201096
[No Abstract] [Full Text] [Related]
30. Alpha-fetoprotein-mediated targeting of anti-cancer drugs to tumor cells in vitro.
Severin SE; Moskaleva EYu ; Shmyrev II; Posypanova GA; Belousova YuV ; Sologub VK; Luzhkov YuM ; Nakachian R; Andreani J; Severin ES
Biochem Mol Biol Int; 1995 Oct; 37(2):385-92. PubMed ID: 8673023
[TBL] [Abstract][Full Text] [Related]
31. Considerations for successful cancer immunotherapy in aged hosts.
Hurez V; Padrón ÁS; Svatek RS; Curiel TJ
Clin Exp Immunol; 2017 Jan; 187(1):53-63. PubMed ID: 27690272
[TBL] [Abstract][Full Text] [Related]
32. Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells.
Payne KK; Keim RC; Graham L; Idowu MO; Wan W; Wang XY; Toor AA; Bear HD; Manjili MH
J Leukoc Biol; 2016 Sep; 100(3):625-35. PubMed ID: 26928306
[TBL] [Abstract][Full Text] [Related]
33. Review of Growth Inhibitory Peptide as a biotherapeutic agent for tumor growth, adhesion, and metastasis.
Muehlemann M; Miller KD; Dauphinee M; Mizejewski GJ
Cancer Metastasis Rev; 2005 Sep; 24(3):441-67. PubMed ID: 16258731
[TBL] [Abstract][Full Text] [Related]
34. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
Parker KH; Beury DW; Ostrand-Rosenberg S
Adv Cancer Res; 2015; 128():95-139. PubMed ID: 26216631
[TBL] [Abstract][Full Text] [Related]
35. Myeloid-derived suppressor cells and tumor escape from immune surveillance.
Umansky V; Blattner C; Fleming V; Hu X; Gebhardt C; Altevogt P; Utikal J
Semin Immunopathol; 2017 Apr; 39(3):295-305. PubMed ID: 27787613
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy of hepatocellular carcinoma with a vaccine based on xenogeneic homologous alpha fetoprotein in mice.
Zhang W; Liu J; Wu Y; Xiao F; Wang Y; Wang R; Yang H; Wang G; Yang J; Deng H; Li J; Wen Y; Wei Y
Biochem Biophys Res Commun; 2008 Nov; 376(1):10-4. PubMed ID: 18725206
[TBL] [Abstract][Full Text] [Related]
37. High-mobility group box protein 1 promotes the survival of myeloid-derived suppressor cells by inducing autophagy.
Parker KH; Horn LA; Ostrand-Rosenberg S
J Leukoc Biol; 2016 Sep; 100(3):463-70. PubMed ID: 26864266
[TBL] [Abstract][Full Text] [Related]
38. Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody.
Dominguez GA; Condamine T; Mony S; Hashimoto A; Wang F; Liu Q; Forero A; Bendell J; Witt R; Hockstein N; Kumar P; Gabrilovich DI
Clin Cancer Res; 2017 Jun; 23(12):2942-2950. PubMed ID: 27965309
[No Abstract] [Full Text] [Related]
39. Amelioration of autoimmune neuroinflammation by recombinant human alpha-fetoprotein.
Irony-Tur-Sinai M; Grigoriadis N; Lourbopoulos A; Pinto-Maaravi F; Abramsky O; Brenner T
Exp Neurol; 2006 Mar; 198(1):136-44. PubMed ID: 16423348
[TBL] [Abstract][Full Text] [Related]
40. Myeloid-derived suppressor cells in immunity and autoimmunity.
Yang H; Bi Y; Han F; Lu Y; Wang J; Zhang Z; Liu G
Expert Rev Clin Immunol; 2015; 11(8):911-9. PubMed ID: 26028421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
